Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae announces expansion of hereditary cancer testing menu

Invitae announces expansion of hereditary cancer testing menu

November 18, 2015

Expanded offering now one of the most comprehensive and includes testing for endocrine, blood, bone, brain, genitourinary, sarcoma, and skin cancers

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its hereditary cancer genetic testing menu, now offering an even more comprehensive testing menu that covers all major hereditary cancers.

Invitae has expanded its test menu to include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma ...

Read more


Invitae announces expansion of its epilepsy test menu

Invitae announces expansion of its epilepsy test menu

November 18, 2015

Invitae now offers an extensive genetic testing panel to better support the needs of clinicians and patients

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its epilepsy testing menu, now offering an extensive panel with more than 100 carefully curated genes that are among the most clinically significant for this life-threatening condition. The menu also includes a smaller panel specifically for early infantile epileptic encephalopathy and one specifically for syndromic forms of epilepsy. Because ...

Read more


Invitae announces third quarter 2015 financial results and raises 2015 volume guidance

Invitae announces third quarter 2015 financial results and raises 2015 volume guidance

November 05, 2015

Expands test menu with more than 600 genes in production and raises 2015 guidance to 17,000-19,000 billable tests delivered for the year

Hosting conference call at 4:45 pm ET / 1:45 pm PT 

Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the third quarter ended September 30, 2015.  The company has raised its 2015 guidance for billable tests delivered to 17,000-19,000 for the year, up from its previous guidance of 16,000-18 ...

Read more


Invitae appoints Christine M. Gorjanc to its Board of Directors

Invitae appoints Christine M. Gorjanc to its Board of Directors

November 05, 2015

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the appointment of Christine M. Gorjanc to its Board of Directors, effective immediately.

Christine currently serves as chief financial officer at NETGEAR, Inc. (NASDAQ: NTGR), a global networking company that delivers innovative products to consumers, businesses, and service providers. Prior to joining NETGEAR as vice president of finance in November 2005, Ms. Gorjanc served as vice president, controller, treasurer, and assistant secretary for Aspect Communications Corporation, a provider of workforce ...

Read more


Invitae to provide testing for Sudden Death in the Young (SDY) Case Registry to advance understanding of sudden death in the young

Invitae to provide testing for Sudden Death in the Young (SDY) Case Registry to advance understanding of sudden death in the young

October 19, 2015

First-of-its-kind collaboration seeks to provide genetic insights to medical examiners and families of victims of sudden death in the young

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has entered into a collaboration with the Sudden Death in the Young (SDY) Case Registry, the first ever active surveillance effort designed to increase understanding of the prevalence, causes and risk factors for sudden death in the young. The Registry is funded by the National Heart, Lung, and ...

Read more


Invitae to announce third quarter 2015 financial results and host conference call on November 5, 2015

Invitae to announce third quarter 2015 financial results and host conference call on November 5, 2015

October 15, 2015

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015, and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 61246482.

The live, listen-only ...

Read more


Invitae expands its offering for rare disease and pediatric conditions with broader, affordable genetic tests

Invitae expands its offering for rare disease and pediatric conditions with broader, affordable genetic tests

October 07, 2015

High-quality genetic tests now available for RASopathies, ciliopathies, and various congenital structural heart defects, patient pay price is $475

More panels for rare diseases to be introduced in coming months 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has started to expand its offering of genetic tests for rare diseases and pediatric conditions, providing broader panels and new testing categories.

Invitae's new test panels for various congenital structural heart defects provide a broad, innovative option ...

Read more


Invitae expands its neuromuscular offering with broad, affordable panels and new testing categories for patients

Invitae expands its neuromuscular offering with broad, affordable panels and new testing categories for patients

October 07, 2015

Now offering high-quality, affordable genetic tests for Duchenne/Becker muscular dystrophy, dystonia, and expanded panels for Charcot-Marie-Tooth disease and hereditary spastic paraplegia

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it now offers genetic testing for neuromuscular diseases, including Duchenne/Becker muscular dystrophy, dystonia, and pediatric neurodevelopmental syndromes. The company also expanded its panels for Charcot-Marie-Tooth disease and hereditary spastic paraplegia, progressive genetic diseases that affect motor and sensory pathways. 

Invitae now has nearly 100 carefully curated genes ...

Read more


Invitae expands its cardiology offering to provide more comprehensive testing for patients and their families

Invitae expands its cardiology offering to provide more comprehensive testing for patients and their families

October 07, 2015

A wide range of high-quality, affordable genetic tests now available for hereditary cardiovascular disorders

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the expansion of its cardiology offering, including more than 30 cardiovascular test panels for arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension, and congenital heart disease.

Genetic cardiac conditions may be difficult to diagnose. Often, the first evidence of a hereditary cardiac condition is the sudden death of an otherwise healthy person, sometimes in infancy or childhood ...

Read more


Invitae expands its hereditary cancer offering

Invitae expands its hereditary cancer offering

October 07, 2015

Now offering new high-quality panels for gastric cancer, for common hereditary cancer, and  for expanded breast, gynecologic, colon, and pancreatic cancer testing 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it is releasing the next generation of comprehensive cancer panels, providing broader panels and new testing categories.

Invitae has now expanded its cancer offering to include more than 40 testing panels. This new offering includes a mix of larger panels, such as expanded test panels for hereditary ...

Read more

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at ir.invitae.com and follow us on Twitter: @invitae and @invitaeIR